Johnson & Johnson
NYSE: JNJ
$143.63
-$0.84 (-0.6%)
Real Time Data Delayed 15 Min.
JNJ Articles
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Published:
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Published:
Credit Suisse has assembled its favorite health care recovery stocks for a recovering base of elective surgeries and for the risk of rising hospitalizations that go well beyond COVID-19.
Published:
If you are a bond and income investor now, times are grim. One analyst says that the best income portfolio now very well may be a collection of high-quality stocks that pay dependable dividends.
Published:
Many investors feel like the key stocks in the market have simply gotten away from them, but those fears are perhaps misguided, according to some key analysts.
Published:
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
Published:
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.
Published:
Here, 24/7 Wall St. offers a preview of what to expect from Delta Air Lines, Netflix, PepsiCo and some of the other most anticipated quarterly results due this week.
Published:
Johnson & Johnson has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Published: